摘要
目的观察重组人白细胞介素-11联合环孢素治疗糖皮质激素无效的原发免疫性血小板减少症的临床疗效。方法选取2009年8月至2011年8月糖皮质激素治疗无效的原发免疫性血小板减少症患者35例，根据治疗方案分为两组，对照组13例采用环孢素治疗，观察组22例在环孢素治疗基础上联合重组人白细胞介素-11治疗。对比观察两组治疗后的临床疗效及血小板计数变化情况。结果观察组的总有效率为90．9％（20／22），明显高于对照组的53．8％（7/13），差异有统计学意义（P〈0．05）。治疗后对照组和观察组血小板计数均较治疗前明显升高[（112．5±15．4）×10^9／L比（13．24±1．8）×10^9／L，（132．7．4±22．3）×10^9／L比（12．94±1．6）×10^9／L，P〈0．05]。治疗后观察组的血小板计数明显高于对照组（P〈0．05）。结论重组人白细胞介素-11联合环孢素治疗糖皮质激素无效的原发免疫性血小板减少症效果好，值得临床推广应用。
Objective To observe the effect of recombinant human interleukin-11 combined with ciclosporin in treatment of glucocorticoid invalid idiopathic thrombocytopenic purpura. Methods From August 2009 to August 2011, 35 cases with glucocorticoid invalid idiopathic thrombocytopenic purpura patients were divided into two groups according to the treatment method： 13 cases in control group were treated with ciclosporin and 22 cases in observation group were treated with recombinant human interleukin-11 at basis of above method. The clinical effect and platelet counts between two groups were compared. Results The total effective rate in observation group was 90.9% （20/22）, which was significantly higher than that in control group [53.8% （7/13）] （P 〈0.05）. After treatment, the platelet counts in both two groups were significantly increased [ control group： （ 112.5 ± 15.4） × 10^9/L vs. （ 13.2 ± 1.8 ） × 109/L; observation group： （ 132.7 ± 22.3 ） × 10^9/L vs. （ 12.9 ± 1.6） × 10^9/L ] （P 〈 0.05 ）. Moreover, the platelet counts after treatment in observation group was significantly more than that in control group （P 〈 0.05）. Conclusion Recombinant human interleukin-ll combined with ciclosporin in treatment of glucocorticoid invalid idiopathic thrombocytopenic purpura is a good treatment scheme, which can be applied in clinic.
出处
《中国医师进修杂志》
2012年第25期27-29,共3页
Chinese Journal of Postgraduates of Medicine
